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Glucocorticoids promote lipolysis in white adipose
tissue (WAT) to adapt to energy demands under stress,
whereas superfluous lipolysis causes metabolic dis-
orders, including dyslipidemia and hepatic steatosis.
Glucocorticoid-induced lipolysis requires the phosphor-
ylation of cytosolic hormone-sensitive lipase (HSL) and
perilipin 1 (Plin1) in the lipid droplet by protein kinase A
(PKA). We previously identified Pik3r1 (also called p85a)
as a glucocorticoid receptor target gene. Here, we
found that glucocorticoids increased HSL phosphoryla-
tion, but not Plin1 phosphorylation, in adipose tissue-
specific Pik3r1-null (AKO) mice. Furthermore, in lipid
droplets, the phosphorylation of HSL and Plin1 and the
levels of catalytic and regulatory subunits of PKA were
increased by glucocorticoids in wild-type mice. How-
ever, these effects were attenuated in AKO mice. In
agreement with reduced WAT lipolysis, glucocorticoid-
initiated hepatic steatosis and hypertriglyceridemia
were improved in AKO mice. Our data demonstrated a
novel role of Pik3r1 that was independent of the regula-
tory function of phosphoinositide 3-kinase in mediating
the metabolic action of glucocorticoids. Thus, the inhi-
bition of Pik3r1 in adipocytes could alleviate lipid disor-
ders caused by excess glucocorticoid exposure.
Endogenous glucocorticoids (GCs) are steroid hormones
released from the adrenal glands in response to stress
signals. During fasting, GCs promote lipolysis in white
adipose tissue (WAT), where triglycerides (TGs) are
hydrolyzed to glycerol and fatty acids as energy fuels.
Glycerol serves a precursor for hepatic gluconeogenesis,
whereas mobilized fatty acids are oxidized in energy-
requiring tissues to produce ATP. However, prolonged GC
exposure results in dyslipidemia, hepatic steatosis, and
insulin resistance (1–3). Although exogenous GCs are fre-
quently prescribed as effective anti-inflammatory agents,
their actions in metabolic tissues pose a therapeutic co-
nundrum (4).
GCs relay their message through the intracellular GC
receptor (GR), which is a transcription factor. GC-induced
adipocyte lipolysis requires de novo protein synthesis
(5–7), which is consistent with the concept that the GR
exerts its main function through modulating gene expres-
sion. Several mechanisms are documented. First, the GCs
increase the transcription of genes encoding lipolytic
enzymes, including adipose TG lipase (ATGL; also called
desnutrin) and hormone-sensitive lipase (HSL) (6,8,9).
ATGL catalyzes the hydrolysis of TG to diacylglycerol,
whereas HSL hydrolyzes diacylglycerol to monoacylglycerol
(10,11). Moreover, GCs elevate the levels of cAMP (12–14),
which activates protein kinase A (PKA). PKA phosphory-
lates HSL in the cytosol and perilipin 1 (Plin1) on the lipid
droplet (10,11). Phosphorylated HSL (pHSL) are mobilized
to the lipid droplet and associate with phosphorylated
Plin1 (pPlin1) (15–17). This anchoring of pHSL to the lipid
droplet is critical, since TGs are stored within the lipid
droplet. Upon phosphorylation of Plin1, the interaction
between Plin1 and CGI-58 is disrupted, which allows the
activation of ATGL by CGI-58 (10,18,19). It has been
shown that GCs exert at least two distinct mechanisms
to elevate cAMP levels in adipocytes. GCs decrease the
expression of Akt (20) and cAMP phosphodiesterase 3B
(PDE3B) to augment cAMP levels (14). Alternatively, GCs
induce the transcription of angiopoietin-like 4 (Angptl4)
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(21), which encodes a secreted protein that activates
cAMP-PKA signaling in adipocytes to stimulate lipolysis
(12). Overall, we propose that GCs promote WAT lipol-
ysis through a network of GR primary target genes, in-
cluding ATGL, HSL, and Angptl4, most of which remain
to be discovered.
We identified Pik3r1 (also called p85a) as a GR primary
target gene in both adipocytes and myotubes with RNA
profiling and chromatin immunoprecipitation sequencing
analysis (8,22). Pik3r1 encodes a regulatory subunit of
phosphoinositide 3-kinase (PI3K), and overexpression of
Pik3r1 reduces insulin signaling in myotubes and hepato-
cytes (22–25). Monomeric Pik3r1 competes with hetero-
dimeric PI3K, which is composed of Pik3r1 and p110 (the
catalytic subunit of PI3K), from binding to insulin recep-
tor substrate-1 (26,27). Since Pik3r1 lacks the catalytic
capacity, insulin signaling is attenuated. Alternatively,
Pik3r1 can potentiate phosphatase and tensin homolog
(PTEN) to inhibit PI3K (28,29). These data illustrate
that an increase in Pik3r1 is negatively associated with
insulin sensitivity.
In adipocytes, insulin suppresses lipolysis partly through
the PI3K-Atk-PDE3B pathway to decrease the levels of
cAMP (30–32). Therefore, GC-induced excess Pik3r1 could
attenuate insulin signaling and in turn promote lipolysis.
To investigate the role of Pik3r1 in lipolysis, we generated
adipose tissue–specific Pik3r1 knockout (AKO) mice. Sur-
prisingly, lack of Pik3r1 did not attenuate the PI3K-Atk-
PDE3B pathway. Instead, we found that the levels of
pPlin1 were significantly decreased in inguinal WAT
(iWAT) and epididymal WAT (eWAT) in AKO mice in re-
sponse to GCs. Furthermore, in lipid droplets of wild-type
(WT) mice, subunits of PKA were increased by GC treat-
ment. However, this action was abolished in AKO mice.
Moreover, pHSL levels in lipid droplets were augmented
by dexamethasone (Dex) in WT mice, and this effect was
not seen in AKO mice. Finally, Dex-induced hepatic steatosis
and hypertriglyceridemia were dramatically improved in
AKO mice. In summary, we have shown that Pik3r1 medi-
ates the metabolic actions of GCs in WAT. Our data under-
score the possibility that antagonists of WAT Pik3r1 may
improve the adverse effects of GC therapeutics.
RESEARCH DESIGN AND METHODS
Mice
Mice with a conditional allele of the Pik3r1 gene flanked
with LoxP sites at exon7 (Pik3r1flox/flox) were provided by
the laboratory of Lewis Cantley (Weill Cornell Medical
College, New York, NY) (33). Mice expressing Cre recom-
binase driven by the adiponectin promoter (AdipoQ-Cre)
(34) were purchased from The Jackson Laboratory.
AKO mice were generated by crossing Pik3r1flox/flox with
AdipoQ-Cre mice. Primer sequences used for genotyping
are listed in Supplementary Table 1. The Office of Labora-
tory Animal Care at the University of California, Berkeley
(AUP-2014–08–6617) approved all animal experiments
conducted.
Free Fatty Acid Measurement
Plasma free fatty acid (FFA) levels were measured by a FFA
quantification kit (MAK044; Sigma-Aldrich, St. Louis, MO).
Ex Vivo Lipolysis Assay
Lipolysis was assessed as previously described (12). Explants
from freshly removed eWAT and iWAT depots (;100 mg)
were incubated at 37°C in 500 mL of Krebs-Ringer buffer
(12 mmol/L HEPES, 121 mmol/L NaCl, 4.9 mmol/L KCl,
1.2 mmol/L MgSO4, and 0.33 mmol/L CaCl2) with 3% BSA
and 3 mmol/L glucose. Media were collected after 1 h of
incubation, and glycerol levels in media were determined
with free glycerol reagent (F6428; Sigma-Aldrich). Measure-
ments were normalized to protein content of the ex-
plants with a protein dye reagent (500–0006; Bio-Rad,
Hercules, CA).
Quantitative Real-Time PCR
Quantitative real-time PCR was performed as previously
described (35). Primer sequences are listed in Supplemen-
tary Table 1.
Isolation of Lipid Droplets
The isolation of lipid droplets was based on a previous
report (36). Freshly removed WAT depots were incubated
at 37°C in Krebs-Ringer buffer (12 mmol/L HEPES,
121 mmol/L NaCl, 4.9 mmol/L KCl, 1.2 mmol/L MgSO4,
and 0.33 mmol/L CaCl2) with 3% BSA, 3 mmol/L glucose,
and collagenase (0.033 g/100 mL). The adipocyte solu-
tion was washed twice with PBS to remove extra collage-
nase, followed by resuspension in 3 mL of disruption
buffer (25 mmol/L Tris-HCl, 100 mmol/L KCl, 1 mmol/L
EDTA, 5 mmol/L EGTA, and protease inhibitor). Cells
were disrupted with a Dounce homogenizer, and the ly-
sate was collected and mixed with an equal volume of
disruption buffer containing 1.08 mol/L sucrose. It was
then sequentially overlaid with 2 mL of 270 mmol/L su-
crose buffer, 135 mmol/L sucrose buffer, and Tris/EDTA/
EGTA buffer (25 mmol/L Tris-HCl, 1 mmol/L EDTA,
1 mmol/L EGTA, pH 7.4). After centrifugation at 150,000g
for 1 h, lipid droplet–enriched fractions were collected
from the top of the gradient and were subjected to
immunoblotting.
Plasma Insulin Measurement
Plasma insulin levels were measured using an ultrasensi-
tive mouse insulin ELISA kit (Crystal Chem Inc., Downers
Grove, IL).
Western Blot and Antibodies
The following antibodies were used in this study: anti-
GAPDH (sc-25778; Santa Cruz Biotechnology, Dallas, TX);
anti-Pik3r1 (4292s; Cell Signaling Technology, Danvers,
MA), anti-ATGL (2138s; Cell Signaling Technology); anti-
Akt (9272s; Cell Signaling Technology); anti–phospho-Akt
(T308) (9275s; Cell Signaling Technology); anti–perilipin
A (ab3526; Abcam, Cambridge, MA); anti–phospho-perilipin
(4856; VALA Sciences, San Diego, CA); anti-HSL (4107s;
Cell Signaling Technology); anti–phospho-HSL (S660)
(4126s; Cell Signaling Technology); anti–PKA-RIa (610609;
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BD Biosciences, San Jose, CA); anti–PKA-RIIb (610625;
BD Biosciences); and anti-PKAa catalytic subunit (C-20)
(sc-903; Santa Cruz Biotechnology). Anti-Ubxd8 antibody
was provided by the laboratory of Dr. James Olzmann
(University of California, Berkeley). The intensity of the
bands was quantified using ImageJ software (National
Institute of Health) and normalized to GAPDH or Ubxd8
as indicated.
PDE Activity Assay
Total protein lysates were prepared from fresh tissues,
and PDE activity was measured with PDELight HTS cAMP
phosphodiesterase kit (LT07–600; Lonza, Anaheim, CA).
Statistics
We used a Student t test, and data were expressed as the
SEM for each group. P values,0.05 were considered to be
significant.
RESULTS
Dex Treatment Increased Pik3r1 Protein in WAT
Depots
We have previously identified Pik3r1 as a GC primary
target gene in 3T3-L1 adipocytes, and here we examined
whether GCs induce Pik3r1 protein levels in vivo. Dex, a
synthetic GC, was administered intraperitoneally for 1, 4,
or 7 days in floxed Pik3r1 mice (33) (Pik3r1flox/flox, referred
to as WT) mice. Compared with PBS injection, Dex treat-
ment increased the levels of Pik3r1 protein by as soon as
1 day by twofold in both iWAT (Fig. 1A) and eWAT (Fig.
1B). By the end of 7 days, Dex elevated Pik3r1 protein
levels by approximately threefold in both adipose depots
(Fig. 1A and B). These results demonstrated that GCs
increase Pik3r1 protein expression in iWAT and eWAT
in vivo.
To study the role of Pik3r1 in GC-promoted lipolysis,
we generated adipose tissue–specific Pik3r1-null mice
with AdipoQ-Cre (34) and floxed Pik3r1 mice (33) and
termed AKO mice for simplicity. To confirm the knockout
efficiency and tissue specificity, we isolated iWAT, eWAT,
liver, and gastrocnemius (GA) muscle from 8-week-old
AKO mice and control littermates. Immunoblotting shows
total ablation of Pik3r1 protein in iWAT and eWAT from
AKO mice, although their expressions are present in both
depots from WT mice (Fig. 1C). Furthermore, Pik3r1 ex-
pression is intact in the liver and GA muscle of AKO mice
(Fig. 1D). These data demonstrated extremely high effi-
ciency and specificity for the knockout line. Importantly,
AKO mice showed no gross phenotype and maintained a
body weight that was similar to that of their control lit-
termates (Fig. 1E).
Dex-Induced WAT Lipolysis Was Absent in AKO Mice
We hypothesize that Pik3r1 mediates Dex-induced lipol-
ysis in iWAT and eWAT. We injected a single dose of Dex
(10 mg/kg body wt) or control PBS in AKO and WT mice.
This dose of Dex was somewhat high. However, pilot
studies in our laboratory have shown that lower doses of
Dex induced a weak lipolytic effect in these mice of mixed
FVB/BL6/SV129 background. Higher doses of Dex pro-
vide a stronger lipolytic response and therefore allow us
to dissect the mechanisms underlying Dex effects. Nota-
bly, another laboratory similarly found that mice contain-
ing the FVB background are less sensitive to GC-regulated
physiological phenotypes (37). Twenty-four hours after
injection, glycerol release from isolated iWAT and eWAT
was measured. The amount of released glycerol indicates
the degree of lipolysis. In WT mice, Dex induced glycerol
release in both iWAT and eWAT explants (Fig. 2A and B).
In contrast, in AKO mice, Dex-stimulated glycerol release
was absent (Fig. 2A and B). Furthermore, we also mea-
sured the levels of plasma FFA, the other product of li-
polysis. Plasma FFA levels were increased in Dex-treated
WT mice (Fig. 2C). However, Dex failed to induce plasma
FFA in AKO mice (Fig. 2C). These results illustrated that
Pik3r1 is required for Dex-initiated WAT lipolysis.
Dex-Stimulated ATGL Expression Was Unaffected in
AKO Mice
To understand the mechanism of impaired Dex-induced
WAT lipolysis in the absence of Pik3r1, we first examined
ATGL, the rate-controlling enzyme in lipolysis. Previous
studies have shown that the expression of ATGL was
highly induced by GCs (8,9). To examine whether Dex-
increased ATGL expression was affected in the absence
of Pik3r1, we treated AKO and WT mice with Dex or
PBS for 24 h and performed protein and mRNA expres-
sion analysis. Consistent with previous reports (12), Dex
elevated ATGL protein and mRNA levels in iWAT and
eWAT of WT mice (Fig. 3A and B). Notably, the absence
of Pik3r1 did not affect the ability of Dex to elevate pro-
tein and mRNA expression of ATGL (Fig. 3A and B).
Dex Induced the Phosphorylation of HSL but Not Plin1
in AKO Mice
A second mechanism in which GC-induced lipolysis is
through phosphorylation of HSL and Plin1 indirectly, and
we tested whether Pik3r1 was required in this process. HSL
and Plin1 are phosphorylated by PKA, at serine 660 for
HSL (38) and serine 517 for Plin1 (39). In iWAT and
eWAT, the levels of total HSL showed an upward trend
in WT and AKO mice treated with Dex but did not reach
statistical significance (Fig. 4A and B). In contrast, pHSL
levels were increased by Dex in iWAT and eWAT from WT
and AKO mice (Fig. 4C). These data showed that a lack of
Pik3r1 did not affect Dex-increased pHSL levels.
In both adipose depots, the levels of total Plin1 displayed
similar levels in WT and AKO mice treated with Dex (Fig.
4D and E). Dex increased pPlin1 in WT mice but failed to do
so in AKO mice (Fig. 4F). Thus, Pik3r1 is essential for Dex
to induce phosphorylation of Plin1.
Pik3r1 Is Dispensable in Dex-Modulated Akt and PDE
Activities
Insulin suppresses WAT lipolysis in part through a PI3K-
Akt-PDE3B pathway, where the secondary messenger cAMP
is degraded and therefore unable to activate PKA. In the
iWAT depot, total Akt protein levels were decreased by Dex
diabetes.diabetesjournals.org Kuo and Associates 1603
in WT mice but were upregulated by Dex in AKO mice (Fig.
5A and B). In contrast, no difference was observed in the
eWAT depot (Fig. 5A and B). This suggests that GCs exert a
depot-specific effect on total Akt protein expression.
For Akt activity, we monitored the phosphorylation
status of Akt at serine 308 (40). In both iWAT and eWAT,
Dex-induced phosphorylation of Akt displayed the same
trend in WT and AKO mice (Fig. 5A and C). Dex did not
affect the levels of FoxO1, a downstream effector of
Akt. However, the effects of Dex on the phosphorylation
status of FoxO1 (phosphorylated FoxO1/FoxO1) were
similar to those of Akt (Supplementary Fig. 1). These
results demonstrated that the effects of Dex on PI3K-
Akt signaling were not affected in Pik3r1-null mice, likely
due to the redundant function of Pik3r2.
We further examined PDE activities. Compared with
control-treated WT mice, control- treated AKO mice and
Dex-treated WT and AKO mice all showed increased PDE
activities in iWAT (Fig. 5D). In eWAT, only Dex-treated WT
mice showed significant PDE activity induction. Although
the elevation of control- and Dex-treated eWAT in AKO
mice did not reach statistical significance, the upward trend
Figure 1—Dex induced Pik3r1 protein expression in iWAT and eWAT. A and B: Eight-week-old male WT mice were injected intraperito-
neally with control PBS or Dex (water-soluble Dex, 5 mg/kg body wt; D2915; Sigma-Aldrich) for 1, 4, or 7 days. Pik3r1 protein expression
was measured with immunoblotting in iWAT (A) and eWAT (B) and was normalized to internal control GAPDH. Representative immunoblots
are shown (n = 3). Error bars represent the SEM of relative Pik3r1 expression level (Dex vs. PBS). *P < 0.05. In 8-week-old male WT and
AKO mice, Pik3r1 expressions were examined in iWAT and eWAT (C) and in GA muscle and liver (D). E: Body weights of WT and AKO mice
were monitored from age 5 to 13 weeks; n = 6. Error bars represent the SEM.
Figure 2—Dex-stimulated WAT lipolysis was abolished in AKO mice. Eight-week-old male WT and AKO mice were administered PBS or
Dex (10 mg/kg body wt) at 10:00 A.M. in the morning. After 24 h (at 10:00 A.M. the next morning), fat pads of iWAT and eWAT were isolated for
lipolysis assays. Relative glycerol release was measured from iWAT (A) and eWAT (B) explants. C: The levels of serum FFAs were
measured. Error bars represent the SEM. n = 7. *P < 0.05.
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demonstrated that their PDE signaling was unchanged
(Fig. 5D).
It was surprising that Dex treatment increased Akt and
PDE activities (Fig. 5C and D), since GCs have been shown
to antagonize insulin signaling in adipocytes (20,41–43).
Moreover, GC-induced excess Pik3r1 did not inhibit Akt
and PDE activities. Notably, the treatment of GCs in vivo
causes hyperinsulinemia, which could explain the elevated
Figure 3—Dex increased ATGL protein and mRNA expression in WT and AKOmice. Eight-week-old male WT and AKOmice were administered
PBS or Dex (10 mg/kg body wt) for 24 h. A: In both iWAT and eWAT, the expression of ATGL was monitored by immunoblots. Representative
results from three independent experiments are shown. Bar graphs show the average intensity of bands. GAPDH was used as an internal
control. B: The mRNA expression level of ATGL was monitored by quantitative real-time PCR. Error bars represent the SEM. *P < 0.05.
Figure 4—Dex effects on HSL and Plin1 phosphorylation in WT and AKO mice. Eight-week-old male WT and AKO mice were administered
PBS or Dex (10 mg/kg body wt) for 24 h. A: In iWAT and eWAT, HSL and pHSL levels are displayed in immunoblots, and GAPDH was used
as an internal control. B: Bar graphs show normalized total HSL protein levels. C: Bar graphs illustrate normalized pHSL protein levels. D: In
iWAT and eWAT, Plin1 and pPlin1 levels are displayed in immunoblots, and GAPDH was used as an internal control. E: Bar graphs show
normalized total Plin1 protein levels. F: Bar graphs illustrate normalized pPlin1 protein levels. Error bars represent the SEM. n = 3. *P< 0.05.
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Akt and PDE activities. To examine this, we measured the
plasma insulin levels in Dex-treated WT and AKO mice.
Indeed, we found that Dex increased insulin levels in WT
mice, and a similar upward trend was observed in AKO
mice (Fig. 5E). These data demonstrated that the PI3K-
Akt-PDE3B pathway was intact even in the absence of
Pik3r1. Thus, Dex-induced PKA signaling was indepen-
dent of the PI3K-Akt-PDE3B pathway.
In the Lipid Droplets, Dex Increased pHSL and
Subunits of PKA Were Attenuated in AKO Mice
We further explored the mechanism of compromised Dex-
induced Plin1 phosphorylation in the absence of Pik3r1 in
the lipid droplet and proposed three scenarios. First, the
amount of PKA in the lipid droplet could be reduced.
Second, the levels of the lipid droplet A kinase–anchoring
protein optic atrophy 1 (OPA1) (44) could decrease. This
results in less anchored PKA in lipid droplets. Third,
pPlin1 could be dephosphorylated more rapidly. We iso-
lated lipid droplets from eWAT from control- or Dex-
treated WT and AKO mice and tested these possibilities.
Pik3r1 is present in lipid droplets in WT mice but not
in AKO mice. Interestingly, Dex did not modulate Pik3r1
protein levels in these lipid droplets (Fig. 6A). In contrast,
Dex increased the phosphorylation of lipid droplet–
associated HSL and Plin1 in WT mice but not in AKO
mice (Fig. 6A–C). Furthermore, Dex increased the levels of
PKA catalytic and regulatory RIIb subunit in lipid droplets
of WT mice but not AKO mice (Fig. 6A, D, and E). OPA1,
however, showed no difference between WT and AKO
mice. Protein phosphatase 1 (PP1) dephosphorylates lipid
droplet–anchored Plin1 (45), and similar levels of PP1 were
detected in WT and AKO mice (Fig. 6A). To test whether
Dex generally increases PKA levels, we monitored different
subunits of PKA in whole-cell lysates of eWAT from WT
and AKO mice treated with Dex, and no difference was
found (Supplementary Fig. 2). Overall, these results indi-
cate that Pik3r1 is indispensable for Dex-increased pPlin1,
pHSL, and PKA levels in lipid droplets.
AKO Mice Were Protected From Dex-Induced Hepatic
Steatosis and Hypertriglyceridemia
Superfluous adipose tissue lipolysis caused by GCs can result
in excess lipid mobilization from WAT to liver, leading to
hepatic steatosis and hypertriglyceridemia. We explored the
possibility that Pik3r1 ablation could relieve GC-induced
symptoms. Dex was administered to WT and AKO mice for
7 days, and their plasma and hepatic TG levels were
measured. Similar levels of hepatic TGs were found in
control-treated WT and AKO mice (Fig. 7A). Dex stimu-
lated hepatic TG levels by 10-fold in WT mice (Fig. 7A).
Markedly, this adverse Dex effect was reduced to only
Figure 5—Dex actions on Akt and PDE activities are intact in the absence of Pik3r1. Eight-week-old male WT and AKO mice were
administered PBS or Dex (10 mg/kg body wt) for 24 h. A: In iWAT and eWAT, Akt and pAkt levels are displayed in immunoblots, and
GAPDH was used as an internal control. B: Bar graphs show normalized total Akt protein levels. C: Bar graphs illustrate normalized pAkt
protein levels. D: In iWAT and eWAT, PDE activities are normalized to PBS-treated WT mice. E: Plasma insulin levels were measured. Error
bars represent the SEM. n = 6. *P < 0.05.
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twofold in AKO mice (Fig. 7A). For plasma TG, levels were
similar between control-treated WT and AKO mice (Fig.
7B). In WT mice, Dex increased plasma TG levels by
twofold (Fig. 7B). However, this effect was abolished
in AKO mice (Fig. 7B). These results demonstrated that
Pik3r1 ablation improves GC-induced hepatic steatosis
and hypertriglyceridemia.
We performed an intraperitoneal glucose tolerance test
in control- and Dex-treated WT and AKO mice. We found
that glucose tolerance was similar between control- and
Dex-treated WT and AKO mice (Supplementary Fig. 3A
and B). Plasma insulin levels were lower in control-treated
AKO mice than in WT mice (Supplementary Fig. 3C). In
both WT and AKO mice, Dex treatment caused hyperin-
sulinemia (Supplementary Fig. 3C). However, plasma in-
sulin levels for Dex-treated AKO mice were significantly
lower than those of Dex-treated WT mice (Supplementary
Fig. 3C). These results suggest that Dex-treated AKO mice
were more insulin sensitive than Dex-treated WT mice.
Norepinephrine-Increased WAT Lipolysis Was Not
Affected in AKO Mice
In addition to GCs, norepinephrine plays a key role in
promoting WAT lipolysis (11). WT and AKO mice were
treated with or without norepinephrine for 20 min. Plasma
FFA levels were then measured. Norepinephrine treatment
significantly increased the levels of plasma FFA in both WT
and AKO mice. The fold induction of norepinephrine was
similar, although plasma FFA levels were slightly lower in
AKO mice (Supplementary Fig. 4A). We isolated eWAT from
WT and AKO mice to perform ex vivo lipolysis assay. We
found that norepinephrine significantly elevated glycerol
release from eWAT explants of WT and AKO mice (Sup-
plementary Fig. 4B). The fold induction of norepinephrine
was similar between WT and AKO eWAT explants (Supple-
mentary Fig. 4B). These results demonstrate that
norepinephrine-induced adipocyte lipolysis is not affected
by lacking Pik3r1.
DISCUSSION
Endogenous GCs are essential for metabolic adaptation in
stressful conditions such as fasting. During fasting, GCs
promote lipolysis in adipose tissues to release glycerol for
hepatic gluconeogenesis and fatty acids as energy fuels
for peripheral tissues. However, during prolonged GC expo-
sure, such as in exogenous anti-inflammation treat-
ment, excess lipolysis can cause metabolic disorders,
including dyslipidemia and insulin resistance. Therefore,
identification of GC targets in adipose tissue is critical to
eliminate the adverse metabolic actions in GC therapeutic
agents. Here, we report that Pik3r1, a regulatory subunit of
PI3K and a GC primary target gene, mediates GC-stimulated
adipocyte lipolysis. With the deletion of Pik3r1 in WAT spe-
cifically, the ability of GCs to induce lipolysis was abolished,
and GC-initiated hepatic steatosis and hypertriglyceridemia
Figure 6—In lipid droplets, Dex induced the levels of pHSL, pPlin1, and subunits of PKA in WAT of WT mice but not AKO mice. Eight-week-
old male WT and AKO mice were administered PBS or Dex (10 mg/kg body wt) for 24 h. A–E: Lipid droplets were isolated from eWAT.
A: Immunoblots display the levels of Pik3r1, pHSL, pPlin1, regulatory subunits of PKA (PKA-RIa and PKA-RIIb), catalytic subunit of PKA
(PKAa-cat), OPA1, PP1, and lipid droplet internal control Ubxd8. B: Bar graphs show normalized pHSL protein levels. C: Bar graphs
show normalized pPlin1 protein levels. D: Bar graphs illustrate normalized PKA-RIIb protein levels. E: Bar graphs demonstrate normalized
PKAa-cat protein levels. Error bars represent the SEM. n = 3. *P < 0.05.
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were alleviated. We then explored the potential mechanisms
of reduced GC-stimulated lipolysis in the absence of Pik3r1.
Because Pik3r1 participates in PI3K-Akt-PDE3B axis,
Pik3r1 deletion could impair this axis therefore antagoniz-
ing cAMP-PKA–induced lipolysis. Unexpectedly, this axis
was very much intact in Pik3r1-null adipocytes upon 24 h
of Dex treatment. Thus, Pik3r1 is involved in GC-promoted
WAT lipolysis through a pathway independent of the PI3K-
Akt axis. Interestingly, although similar levels of pHSL were
found in whole-cell lysates in the WAT of WT and AKO
mice in response to GC treatment, its levels in lipid droplets
of WAT in AKO mice were markedly reduced. This is likely
due to the reduced pPlin1 levels in WAT of Dex-treated
AKO mice because the PKA phosphorylation of Plin1 is
required for its recruitment of pHSL to the lipid droplet
(46,47). Notably, subunits of PKA in lipid droplets were
increased by GC treatment in WT mice but not AKO mice,
whereas their levels in whole-cell lysates were similar in both
mouse models. On the basis of these results, we propose
that without Pik3r1 in adipocytes, the ability of Dex to in-
crease PKA levels in the lipid droplet is impaired, resulting in
reduced pPlin1 levels in the lipid droplet (Fig. 8). As a result,
the levels of GC-induced pHSL levels were eradicated in the
lipid droplet, which caused the impairment of lipolysis
(Fig. 8). Thus, Pik3r1 plays a role in recruiting PKA to the
lipid droplet in conveying GC-induced adipocyte lipolysis.
Notably, upon a prolonged Dex exposure it is possible that
the role of Pik3r1 in the regulation of insulin sensitivity is
involved in the modulation of WAT lipolysis. This specula-
tion is based on the fact that AKO mice were more insulin
sensitive than WT mice upon 7 days of Dex treatment.
Moreover, the improvement of insulin sensitivity could
also contribute to improved hepatic steatosis and hyper-
triglyceridemia phenotypes in Dex-treated AKO mice.
Figure 7—AKO mice are protected from Dex-induced hepatic steatosis and hypertriglyceridemia. Eight-week-old male WT and AKO mice
were administered PBS or Dex (10 mg/kg body wt) for 7 days. Hepatic TG (A) and plasma TG (B) levels were assessed. For plasma TGs,
mice were fasted for 6 h prior to sample collection. Error bars represent the SEM. n = 6. *P < 0.05.
Figure 8—A model for the role of Pik3r1 in GC-stimulated WAT lipolysis. In WAT, PI3K-Akt-PDE3B signaling was intact in the absence of
Pik3r1 (in gray). A: In the presence of Pik3r1, GC treatment augments cAMP-PKA signaling, leading to the phosphorylation of HSL in the
cytosol. In the lipid droplets, PKA levels, which in turn phosphorylate Plin1, are increased. pPlin1 can then anchor pHSL from the cytosol to
lipid droplets for TG hydrolysis. B: In the absence of Pik3r1, GC-induced cAMP-PKA signaling is still able to phosphorylate cytosolic HSL.
However, GCs did not increase PKA levels in the lipid droplet. Plin1 cannot be phosphorylated, and pHSL is unable to anchor to the lipid
droplet; therefore, minimal lipolysis was observed. Red arrows indicate the reduction of levels in lipid droplet. FA, fatty acid.
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So, how is Pik3r1 involved in GC-increased PKA levels in
the lipid droplet? OPA1 plays a key role in anchoring PKA
in the lipid droplet to phosphorylate Plin1 upon catechol-
amine stimulation (44). However, our studies showed that
GC treatment did not affect the levels of OPA1 in the lipid
droplet. We cannot exclude the possibility that GCs induce
post-translational modifications of OPA1 to increase the
retention of PKA in the lipid droplet. Alternatively, GCs
could increase the trafficking of PKA to the lipid droplet.
Pik3r1 has been shown to participate in the trafficking
of receptor tyrosine kinases and erythropoietin receptor
(48,49) and is required for the nuclear localization of
XBP1 (50,51). Another possibility is that Pik3r1 is involved
in PKA stability in the lipid droplet. Pik3r1 has been shown
to interact with PTEN and blocks ubiquitination of PTEN
and its eventual proteasomal degradation (52). Future ex-
periments are necessary to determine which of these mech-
anisms are exerted by Pik3r1 to increase PKA levels in the
lipid droplet upon GC treatment.
We have previously shown that Angptl4, another GR
primary target gene (21), is involved in GC-induced adi-
pocyte lipolysis. Angptl4 encodes a secreted protein that
directly increases cAMP levels in adipocytes to promote
lipolysis. In Angptl4-null mice, PKA-initiated phosphory-
lation of HSL and Plin1 induced by Dex are significantly
reduced (12). Thus, Angptl4 acts upstream of Pik3r1 in
GC-induced adipose lipolysis. In this view, it would be
interesting to examine whether Angptl4-induced adipose
lipolysis requires Pik3r1.
Notably, norepinephrine also activates cAMP-PKA
signaling to stimulate lipolysis. However, Pik3r1 is not
required for norepinephrine-induced adipocyte lipolysis. In
contrast to GCs, norepinephrine does not increase Pik3r1
expression in adipocytes. We speculate that in normal
physiological states, the majority of Pik3r1 is associated with
the catalytic subunit of PI3K. GCs increase the levels of
Pik3r1, which in turn can participate in lipolysis in adipo-
cytes. This model will need to be examined in a future
study.
In summary, our studies have identified a novel role of
Pik3r1 in GC-augmented PKA levels in the lipid droplet to
promote lipolysis. Removal of Pik3r1 in WAT dampens the
ability of GCs to promote lipolysis, which leads to hyper-
triglyceridemia and fatty liver. Thus, WAT Pik3r1 is a
potential target to lessen lipid disorders caused by GCs.
The mechanisms underlying the regulation of PKA levels in
the lipid droplet that leads to the modulation of lipolysis is
mostly unknown, and future studies are warranted.
Acknowledgments. The authors thank Dr. Hei Sook Sul (University of
California, Berkeley) for comments on the manuscript.
Funding. This work was supported by National Institutes of Health/National
Institute of Diabetes and Digestive and Kidney Diseases grant R01-DK-
083591. T.K. is supported by the Dissertation Award Fellowship from the
University of California Tobacco-Related Diseases Research Program. T.-C.C. is
supported by the Dr. and Mrs. James C.Y. Soong Fellowship from the University of
California.
Duality of Interest. No potential conflicts of interest relevant to this article
were reported.
Author Contributions. T.K. and T.-C.C. contributed to the conceptual-
ization and methodology of the study, the performance of investigations, and the
writing of the article. R.A.L. contributed to the performance of investigations
and the writing of the article. N.H.T.N., A.E.B., and D.Z. contributed to the
performance of investigations. J.-C.W. contributed to the conceptualization and
methodology of the study, the acquisition of funding, supervision of the study,
and writing of the article. J.-C.W. is the guarantor of this work and, as such, had
full access to all the data in the study and takes responsibility for the integrity of
the data and the accuracy of the data analysis.
References
1. Kuo T, McQueen A, Chen TC, Wang JC. Regulation of glucose homeostasis
by glucocorticoids. Adv Exp Med Biol 2015;872:99–126
2. de Guia RM, Herzig S. How do glucocorticoids regulate lipid metabolism?
Adv Exp Med Biol 2015;872:127–144
3. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid me-
tabolism in humans: fuelling fat redistribution in the metabolic syndrome.
J Endocrinol 2008;197:189–204
4. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new
mechanisms for old drugs. N Engl J Med 2005;353:1711–1723
5. Campbell JE, Peckett AJ, D’souza AM, Hawke TJ, Riddell MC. Adipogenic
and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol
2011;300:C198–C209
6. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose
tissue lipid metabolism. Metabolism 2011;60:1500–1510
7. Fain JN, Dodd A, Novak L. Enzyme regulation in gluconeogenesis and
lipogenesis. Relationship of protein synthesis and cyclic AMP to lipolytic action
of growth hormone and glucocorticoids. Metabolism 1971;20:109–118
8. Yu CY, Mayba O, Lee JV, et al. Genome-wide analysis of glucocorticoid
receptor binding regions in adipocytes reveal gene network involved in tri-
glyceride homeostasis. PLoS One 2010;5:e15188
9. Villena JA, Roy S, Sarkadi-Nagy E, Kim KH, Sul HS. Desnutrin, an adi-
pocyte gene encoding a novel patatin domain-containing protein, is induced
by fasting and glucocorticoids: ectopic expression of desnutrin increases
triglyceride hydrolysis. J Biol Chem 2004;279:47066–47075
10. Young SG, Zechner R. Biochemistry and pathophysiology of intravascular
and intracellular lipolysis. Genes Dev 2013;27:459–484
11. Duncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS. Regulation of
lipolysis in adipocytes. Annu Rev Nutr 2007;27:79–101
12. Gray NE, Lam LN, Yang K, Zhou AY, Koliwad S, Wang JC. Angiopoietin-like
4 (Angptl4) protein is a physiological mediator of intracellular lipolysis in murine
adipocytes. J Biol Chem 2012;287:8444–8456
13. Koliwad SK, Gray NE, Wang JC. Angiopoietin-like 4 (Angptl4): a glucocorticoid-
dependent gatekeeper of fatty acid flux during fasting. Adipocyte 2012;1:182–187
14. Xu C, He J, Jiang H, et al. Direct effect of glucocorticoids on lipolysis in
adipocytes. Mol Endocrinol 2009;23:1161–1170
15. Moore HP, Silver RB, Mottillo EP, Bernlohr DA, Granneman JG. Perilipin
targets a novel pool of lipid droplets for lipolytic attack by hormone-sensitive
lipase. J Biol Chem 2005;280:43109–43120
16. Brasaemle DL, Subramanian V, Garcia A, Marcinkiewicz A, Rothenberg A.
Perilipin A and the control of triacylglycerol metabolism. Mol Cell Biochem 2009;
326:15–21
17. Sztalryd C, Kimmel AR. Perilipins: lipid droplet coat proteins adapted for
tissue-specific energy storage and utilization, and lipid cytoprotection. Biochimie
2014;96:96–101
18. Subramanian V, Rothenberg A, Gomez C, et al. Perilipin A mediates the
reversible binding of CGI-58 to lipid droplets in 3T3-L1 adipocytes. J Biol Chem
2004;279:42062–42071
19. Granneman JG, Moore HP, Krishnamoorthy R, Rathod M. Perilipin
controls lipolysis by regulating the interactions of AB-hydrolase containing
diabetes.diabetesjournals.org Kuo and Associates 1609
5 (Abhd5) and adipose triglyceride lipase (Atgl). J Biol Chem 2009;284:34538–
34544
20. Burén J, Lai YC, Lundgren M, Eriksson JW, Jensen J. Insulin action and
signalling in fat and muscle from dexamethasone-treated rats. Arch Biochem
Biophys 2008;474:91–101
21. Koliwad SK, Kuo T, Shipp LE, et al. Angiopoietin-like 4 (ANGPTL4, fasting-
induced adipose factor) is a direct glucocorticoid receptor target and participates
in glucocorticoid-regulated triglyceride metabolism. J Biol Chem 2009;284:
25593–25601
22. Kuo T, Lew MJ, Mayba O, Harris CA, Speed TP, Wang JC. Genome-wide
analysis of glucocorticoid receptor-binding sites in myotubes identifies gene
networks modulating insulin signaling. Proc Natl Acad Sci U S A 2012;109:
11160–11165
23. Barbour LA, Mizanoor Rahman S, Gurevich I, et al. Increased P85alpha is a
potent negative regulator of skeletal muscle insulin signaling and induces in vivo
insulin resistance associated with growth hormone excess. J Biol Chem 2005;
280:37489–37494
24. Draznin B. Molecular mechanisms of insulin resistance: serine phosphor-
ylation of insulin receptor substrate-1 and increased expression of p85alpha: the
two sides of a coin. Diabetes 2006;55:2392–2397
25. Taniguchi CM, Aleman JO, Ueki K, et al. The p85alpha regulatory subunit of
phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin
resistance. Mol Cell Biol 2007;27:2830–2840
26. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. The p85 regulatory
subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the
formation of a sequestration complex. J Cell Biol 2005;170:455–464
27. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR.
Molecular balance between the regulatory and catalytic subunits of phosphoi-
nositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 2002;22:
965–977
28. Cheung LW, Walkiewicz KW, Besong TM, et al. Regulation of the PI3K
pathway through a p85a monomer-homodimer equilibrium. eLife 2015;4:
e06866
29. Chagpar RB, Links PH, Pastor MC, et al. Direct positive regulation of PTEN
by the p85 subunit of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A
2010;107:5471–5476
30. Degerman E, Ahmad F, Chung YW, et al. From PDE3B to the regulation of
energy homeostasis. Curr Opin Pharmacol 2011;11:676–682
31. Degerman E, Landström TR, Wijkander J, et al. Phosphorylation and acti-
vation of hormone-sensitive adipocyte phosphodiesterase type 3B. Methods
1998;14:43–53
32. Kitamura T, Kitamura Y, Kuroda S, et al. Insulin-induced phosphorylation
and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine
kinase Akt. Mol Cell Biol 1999;19:6286–6296
33. Luo J, McMullen JR, Sobkiw CL, et al. Class IA phosphoinositide 3-kinase
regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 2005;25:
9491–9502
34. Eguchi J, Wang X, Yu S, et al. Transcriptional control of adipose lipid
handling by IRF4. Cell Metab 2011;13:249–259
35. Kuo T, Liu PH, Chen TC, et al. Transcriptional regulation of FoxO3 gene by
glucocorticoids in murine myotubes. Am J Physiol Endocrinol Metab 2016;310:
E572–E585
36. Blouin CM, Le Lay S, Eberl A, et al. Lipid droplet analysis in caveolin-
deficient adipocytes: alterations in surface phospholipid composition and
maturation defects. J Lipid Res 2010;51:945–956
37. Watson ML, Baehr LM, Reichardt HM, Tuckermann JP, Bodine SC, Furlow
JD. A cell-autonomous role for the glucocorticoid receptor in skeletal muscle
atrophy induced by systemic glucocorticoid exposure. Am J Physiol Endocrinol
Metab 2012;302:E1210–E1220
38. Su CL, Sztalryd C, Contreras JA, Holm C, Kimmel AR, Londos C. Mutational
analysis of the hormone-sensitive lipase translocation reaction in adipocytes.
J Biol Chem 2003;278:43615–43619
39. Zhang HH, Souza SC, Muliro KV, Kraemer FB, Obin MS, Greenberg AS.
Lipase-selective functional domains of perilipin A differentially regulate consti-
tutive and protein kinase A-stimulated lipolysis. J Biol Chem 2003;278:51535–
51542
40. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of
protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541–6551
41. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal
role in multiple forms of insulin resistance. Nature 2006;440:944–948
42. Burén J, Liu HX, Jensen J, Eriksson JW. Dexamethasone impairs insulin
signalling and glucose transport by depletion of insulin receptor substrate-1,
phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adi-
pocytes. Eur J Endocrinol 2002;146:419–429
43. Wang Y, Yan C, Liu L, et al. 11b-Hydroxysteroid dehydrogenase type 1
shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in
mouse abdominal adipose tissue. Am J Physiol Endocrinol Metab 2015;308:
E84–E95
44. Pidoux G, Witczak O, Jarnæss E, et al. Optic atrophy 1 is an A-kinase
anchoring protein on lipid droplets that mediates adrenergic control of lipolysis.
EMBO J 2011;30:4371–4386
45. Clifford GM, McCormick DK, Londos C, Vernon RG, Yeaman SJ. De-
phosphorylation of perilipin by protein phosphatases present in rat adipocytes.
FEBS Lett 1998;435:125–129
46. Sztalryd C, Xu G, Dorward H, et al. Perilipin A is essential for the trans-
location of hormone-sensitive lipase during lipolytic activation. J Cell Biol 2003;
161:1093–1103
47. Wang H, Hu L, Dalen K, et al. Activation of hormone-sensitive lipase re-
quires two steps, protein phosphorylation and binding to the PAT-1 domain of
lipid droplet coat proteins. J Biol Chem 2009;284:32116–32125
48. Chamberlain MD, Berry TR, Pastor MC, Anderson DH. The p85alpha subunit
of phosphatidylinositol 39-kinase binds to and stimulates the GTPase activity of
Rab proteins. J Biol Chem 2004;279:48607–48614
49. Bulut GB, Sulahian R, Yao H, Huang LJ. Cbl ubiquitination of p85 is essential
for Epo-induced EpoR endocytosis. Blood 2013;122:3964–3972
50. Park SW, Zhou Y, Lee J, et al. The regulatory subunits of PI3K, p85alpha
and p85beta, interact with XBP-1 and increase its nuclear translocation. Nat Med
2010;16:429–437
51. Winnay JN, Boucher J, Mori MA, Ueki K, Kahn CR. A regulatory subunit of
phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding
protein-1 to modulate the unfolded protein response. Nat Med 2010;16:438–445
52. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2
mutations in endometrial cancer elucidates a novel mechanism for regulation of
PTEN protein stability. Cancer Discov 2011;1:170–185
1610 Pik3r1 and Glucocorticoid-Induced Lipolysis Diabetes Volume 66, June 2017
